- Home
- ECX vs EDIT Comparison
ECX vs EDIT Comparison
Compare ECX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECX | EDIT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.6M | 432.8M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ECX | EDIT |
|---|---|---|
| Price | $0.89 | $2.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $3.05 | ★ $6.10 |
| AVG Volume (30 Days) | 921.0K | ★ 2.4M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $29.03 | N/A |
| Revenue Next Year | $18.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $0.79 | $1.66 |
| 52 Week High | $2.70 | $3.94 |
Technical Indicators
Market Signals| Indicator | ECX | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 46.54 |
| Support Level | $0.79 | $2.31 |
| Resistance Level | $1.14 | $2.87 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 58.00 | 40.69 |
Price Performance
Historical ComparisonAbout ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the Peoples Republic of China. The companies core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.